
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …

Ipsen has announced the agreement to acquire oncology assets from Merrimack Pharmaceuticals, most notably the pancreatic cancer drug Onivyde, in …

Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …

